Company Overview and News

2
Why Is Intuit (INTU) Up 3.8% Since Last Earnings Report?

8h zacks
It has been about a month since the last earnings report for Intuit (INTU - Free Report) . Shares have added about 3.8% in that time frame, outperforming the S&P 500.
INTU RAVN

61
Sino-US Trade Relations Turn Sour: Winners & Losers

2018-09-18 zacks
President Trump’s administration has announced massive tariffs on Chinese imports, perhaps a move toward a full-fledged trade war with China.
ROP AYI BLT TXN BHPBF MDP WMT AYI.WI BABA INTU AMZN BHP MDPEB AAPL BBL BHP CSX BHPLF ROK

2
7 Large Companies That Easily Could More Than Double Their Dividends

2018-09-18 247wallst
It is no secret that investors love their dividends. After all, those dividends can account for up to half of an investor’s total return over time. And when it comes to dividends for long-term holders, those investors really love to see when their company raises its dividends year after year.
INTU FDX

2
Can you deduct an Apple Watch as a medical expense?

2018-09-17 marketwatch
Apple’s AAPL, -2.38% latest Apple Watch, the Series 4, is packed with health-monitoring features that were approved by the U.S. Food and Drug Administration. Wearers can take electrocardiograms on their wrists and even receive warnings if their heartbeat becomes irregular. So does the Apple Watch counts as a medical device for tax purposes?
INTU WKL

10
Forget FAANGs, Focus on Software ETFs

2018-09-13 zacks
The technology-heavy Nasdaq has been the biggest winner in the bull market and has returned 15.5% year to date. Within this space, the software ETFs have performed exceedingly well throughout the year, with Invesco Dynamic Software ETF (PSJ - Free Report) returning 38% year to date. The other two — SPDR S&P Software & Services ETF (XSW - Free Report) and iShares North American Tech-Software ETF (IGV - Free Report) — have returned 32% and 30%, respectively, year to date.
IGV INTU XSW OXY CRM ACXM

7
Technology ETF (PSJ) Hits New 52-Week High

2018-09-13 zacks
For investors seeking momentum, Invesco Dynamic Software ETF (PSJ - Free Report) ) is probably on radar now. The fund just hit a 52-week high, and is up more than 46% from its 52-week low price of $60.14/share. But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed: PSJ in Focus It tracks the Dynamic Software Intellidex Index.
INTU OXY

78
Investors Should Be Cautious About Buying Square Stock

2018-09-12 investorplace - 1
Even though tech stocks have come under pressure lately, Square (NYSE:SQ) stock has been unaffected by that trend. The company remains a red-hot momentum play. During the past year, Square stock has generated a sizzling return of 242%.
WFCNP PYPL BAC USB TWTR AAPL BBT WFC SQ COF INTU JPM PNC

3
Intuit (INTU) Hits 52-Week High: What's Driving the Stock?

2018-09-04 zacks
Share price of Intuit, Inc. (INTU - Free Report) rallied to a new 52-week high of $298.78, eventually closing a tad lower at $219.47 on Sep 3. The stock has rallied 39.1% year to date, substantially outperforming the 26.2% gain of the industry it belongs to. The stock price momentum can be attributed to consistent results. We note that the company beat the Zacks Consensus Estimate in the trailing four quarters, delivering an average positive surprise of 41.
INTU MSFT CVLT AZPN

2
Intuit: Why Are Executives Leaving?

2018-08-30 seekingalpha
INTU recently announced that its long-time CEO and CTO are both leaving at around the same time.
BNC INTU SANT SAN

11
The Zacks Analyst Blog Highlights: Oracle, Intuit, Regeneron, Macy's and Deere

2018-08-29 zacks - 1
Chicago, IL –August 29, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Oracle (ORCL - Free Report) , Intuit (INTU - Free Report) , Regeneron Pharmaceuticals (REGN - Free Report) , Macy's (M - Free Report) and Deere (DE - Free Report) .
ECR INTU REGN M URBN ORCL

11
Top Stock Reports for Oracle, Intuit & Regeneron Pharmaceuticals

2018-08-28 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Intuit (INTU) and Regeneron Pharmaceuticals (REGN). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
SOJA STZ.B SO REGN BURL DB M STZ QSR.WI EOG INTU CSX QSR ORCL

16
Here Is Why The Market Hit New Highs This Past Week, And Why It Can Continue

2018-08-27 seekingalpha - 2
As a professional money manager, I spent about 50 hours this past week fishing as many tributaries of the market as I could. I made a lot of observations during my travels that I believe can be very helpful to investors.
SPLK INTU FB TGT V VEEV WEED PANW NFLX ADSK CGC

2
Intuit: Looking Ahead To FY19 Risks

2018-08-25 seekingalpha
Looking ahead to FY19, the company is expecting relatively modest 8-10% y/y revenue growth and 11-12% y/y EPS growth.
INTU

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to INTU / Intuit Inc. on message board site Silicon Investor.

Intuitive Surgical, Inc. (ISRG) Intuitive Surgical, Inc. (ISRG) Intuitive Surgical, Inc. (ISRG) Quicken - Problems and Answers.... Quicken - Problems and Answers.... Quicken - Problems and Answers....
Intuit -- Whatu0027s Its Future? Intuit -- Whatu0027s Its Future? Intuit -- Whatu0027s Its Future? I need to quintuple $20,000 I need to quintuple $20,000 I need to quintuple $20,000
Intuit Intuit Intuit Quintus (QNTS) Quintus (QNTS) Quintus (QNTS)
ISRG - Intuitive Surgical ISRG - Intuitive Surgical ISRG - Intuitive Surgical Intuition Intuition Intuition
INTUIT - Will it die? INTUIT - Will it die? INTUIT - Will it die? Quintus Corp. Quintus Corp. Quintus Corp.
CUSIP: 461202103